Skip to main content

ASCO: Vepdegestrant Ups Survival in ER+, HER2− Advanced Breast Cancer With ESR1 Mutations

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on June 2, 2025.

via HealthDay

MONDAY, June 2, 2025 -- For patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer, the oral proteolysis-targeting chimera ER degrader, vepdegestrant, leads to significantly longer progression-free survival in patients with ESR1 mutations, according to a study published online May 31 in the New England Journal of Medicine. The research was presented to coincide with the annual meeting of the American Society of Clinical Oncology, held from May 31 to June 4 in Chicago.

Mario Campone, M.D., Ph.D., from the Institut de Cancérologie de l'Ouest Angers-Nantes in Saint-Herblain, France, and colleagues conducted a phase 3, open-label, randomized trial involving patients with ER-positive, HER2-negative advanced breast cancer who had received one previous line of cyclin-dependent kinase 4 and 6 inhibitor therapy plus one line of endocrine therapy. Patients were randomly assigned to receive vepdegestrant at a dose of 200 mg orally once every day of each 28-day cycle or fulvestrant at a dose of 500 mg on day 1 and day 15 of cycle 1 and on day 1 of subsequent cycles (313 and 311 patients, respectively).

The researchers found that median progression-free survival was 5.0 and 2.1 months with vepdegestrant and fulvestrant, respectively, among the 270 patients with ESR1 mutations (hazard ratio, 0.58). Median progression-free survival was 3.8 and 3.6 months with vepdegestrant and fulvestrant, respectively, among all patients. In 23.4 and 17.6 percent of the patients in the vepdegestrant and fulvestrant groups, respectively, adverse events of grade 3 or higher occurred; adverse events leading to discontinuation occurred in 2.9 and 0.7 percent, respectively.

"Additional follow-up is needed to further characterize the long-term efficacy and safety of vepdegestrant in this population," the authors write.

The study was funded by Pfizer, which is developing vepdegestrant.

Abstract/Full Text (subscription or payment may be required)

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Read this next

Nearly Half With Early-Stage Breast Cancer Extend Endocrine Therapy Beyond Five Years

FRIDAY, June 20, 2025 -- Nearly 40 percent of women with stage I breast cancer and two-thirds with stage II decide to extend endocrine therapy, according to a study published...

Odds of Advanced Cancer, Breast Cancer Death Lower in Screen-Detected Disease

THURSDAY, June 5, 2025 -- For patients aged 40 years or older, screen-detected breast cancer is associated with lower odds of advanced cancer, mastectomy, and breast...

Nodal Irradiation Does Not Reduce Recurrence, Death for ypN0 Breast Cancer

THURSDAY, June 5, 2025 -- For patients with node-positive breast cancer who become pathologically tumor-free with negative axillary nodes (ypN0) after neoadjuvant chemotherapy...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.